Clinical ResearchCardiometabolic RiskAngiotensin-Converting Enzyme Inhibitor, Angiotensin Receptor Blocker Use, and Mortality in Patients With Chronic Kidney Disease
Cardiometabolic Risk
Under an Elsevier user license
open archive
Key Words
angiotensin-converting enzyme inhibitors
angiotensin receptor blockers
chronic kidney disease
mortality
Abbreviations and Acronyms
ACEI
angiotensin-converting enzyme inhibitor
ARB
angiotensin receptor blocker
CHF
congestive heart failure
CKD
chronic kidney disease
eGFR
estimated glomerular filtration rate
OR
odds ratio
RCT
randomized controlled trial
Cited by (0)
This study was supported by grant 1R01DK078106-01 to Drs. Kalantar-Zadeh and Kovesdy and by the Department of Veterans Affairs. Opinions expressed in this paper are those of the authors and do not necessarily represent the opinion of the Department of Veterans Affairs. Mr. Lott and Drs. Malakauskas and Kovesdy are employees of the Department of Veterans Affairs. Dr. Quarles receives research support from Amgen. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.